Clinical trial
Study on the Safety and Effectiveness of VELCADE® in the Treatment of…
NCT00408928 · Sidney Kimmel Cancer Center at Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00408928 |
|---|---|
| Title | Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease |
| Official title | Phase II Trial of VELCADE® (Bortezomib) for Steroid Refractory Acute GVHD |
| Lead sponsor | Sidney Kimmel Cancer Center at Thomas Jefferson University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft-versus-Host Disease |
| Intervention type | Drug |
| Interventions | Bortezomib |
| Enrollment | 11 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2009 |
| First posted | Dec 8, 2006 |
| Last update posted | May 4, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: